Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Cash & Equivalents (2020 - 2025)

Candel Therapeutics' Cash & Equivalents history spans 4 years, with the latest figure at $35.4 million for Q4 2023.

  • On a quarterly basis, Cash & Equivalents fell 49.45% to $35.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $35.4 million, a 49.45% decrease, with the full-year FY2023 number at $35.4 million, down 49.45% from a year prior.
  • Cash & Equivalents hit $35.4 million in Q4 2023 for Candel Therapeutics, down from $43.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CADL hit a ceiling of $94.3 million in Q1 2022 and a floor of $24.3 million in Q2 2021.
  • Historically, Cash & Equivalents has averaged $62.4 million across 4 years, with a median of $64.7 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: soared 256.89% in 2022 and later tumbled 49.45% in 2023.
  • Tracing CADL's Cash & Equivalents over 4 years: stood at $35.1 million in 2020, then surged by 135.76% to $82.6 million in 2021, then decreased by 15.23% to $70.1 million in 2022, then tumbled by 49.45% to $35.4 million in 2023.
  • Business Quant data shows Cash & Equivalents for CADL at $35.4 million in Q4 2023, $43.0 million in Q3 2023, and $51.9 million in Q2 2023.